Renovacor is a preclinical stage biotechnology company whose mission is to develop improved therapies for genetically derived cardiovascular diseases. The company is currently developing a gene therapy for a rare, familial form of dilated cardiomyopathy. Renovacor's lead gene therapy product aims to restore cardiac function in patients with symptomatic heart failure due to BAG3 gene mutation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/14/19 | $11,000,000 | Series A |
BioAdvance Broadview Ventures Innogest Capital New Leaf Venture Partners Novartis Venture Funds | undisclosed |
